Erratum: Ocular toxicities associated with targeted anticancer agents: An analysis of clinical data with management suggestions (Oncotarget (2017) 8 (58709-58727) DOI: 10.18632/oncotarget.17634);Ocular toxicities associated with targeted anticancer agents: An analysis of clinical data with management suggestions

Oncotarget

Volumn 8, Issue 35, 2017, Pages 58709-58727

  Fu, Chen ^a   Gombos, Dan S ^c   Lee, Jared ^b   George, Goldy C ^c   Hess, Kenneth ^c   Whyte, Andrew ^c   Hong, David S ^c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Management; Ocular; Targeted; Toxicity

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BORTEZOMIB; CERITINIB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; IPILIMUMAB; NILOTINIB; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; TRAMETINIB; VANDETANIB; VEMURAFENIB; VERVOY;

ARTICLE; CANCER PATIENT; DISEASE SEVERITY; EYE TOXICITY; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS; PATIENT CARE; SYSTEMATIC REVIEW; VISUAL ACUITY;

EID: 85029044010     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17634     Document Type: Erratum

References (81)

1. Centerwatch Database of FDA Approved Drugs. http://www.centerwatch.com.
2. Agustoni F, Platania M, Vitali M, Zilembo N, Haspinger E, Sinno V, Gallucci R, de Braud F, Garassino MC. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014; 40: 197-203.
3. al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy. A review. Cancer. 1996; 78: 1359-73.
4. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol. 2012; 30: 3277-86.
5. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008; 77: 311-9.
6. Huillard O, Bakalian S, Levy C, Desjardins L, Lumbroso-Le Rouic L, Pop S, Sablin MP, Le Tourneau C. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer. 2014; 50: 638-48.
7. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK. A safety review and metaanalyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One. 2012; 7: e42701.
8. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358: 1160-74.
9. Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs. 2007; 30: S10-6.
10. Liu Z, Xie Y. Epidermal growth factor and its receptors family on the ocular surface. Yan Ke Xue Bao. 1999; 15: 146-52.
11. Liu Y, Liu ZG. [Role of epidermal growth factor and its receptor family in ocular surface wound healing]. [Article in Chinese]. Zhonghua Yan Ke Za Zhi. 2007; 43: 953-6.
12. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009; 283: 125-34.
13. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26: 3291-310.
14. Fraunfelder FW, Yang HK. Association between bortezomib therapy and eyelid chalazia. JAMA Ophthalmol. 2016; 134: 88-90.
15. Yun C, Mukhi N, Kremer V, Shinder R, Verma V, Olcay B. Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy. Hematol Rep. 2015; 7: 5729.
16. Grob SR, Jakobiec FA, Rashid A, Yoon MK. Chalazia associated with bortezomib therapy for multiple myeloma. Ophthalmology. 2014; 121: 1845-7.e3.
17. Draganova D, Kerger J, Caspers L, Willermain F. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthalmic Inflamm Infect. 2015; 5: 17.
18. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15: 700-12.
19. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011; 118: 415-22.
20. Chan RY, Kwok AK. Ocular toxicity of ethambutol. Hong Kong Med J. 2006; 12: 56-60.
21. van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev. 2013; 39: 664-72.
22. National Cancer Institute (U.S.). Common terminology criteria for adverse events (CTCAE). Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. 2009.
23. Chun SG, Iyengar P, Gerber DE, Hogan RN, Timmerman RD. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation. J Clin Oncol. 2015; 33: e25-6.
24. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6: 803-12.
25. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2000; 2: 45-59.
26. Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs. 2011; 3: 153-60.
27. Margolin K. Ipilimumab in a Phase II trial of melanoma patients with brain metastases. Oncoimmunology. 2012; 1: 1197-9.
28. Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol. 2006; 177: 8448-55.
29. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010; 120: 1368-79.
30. Gilotrif (Afatinib) FDA Package Insert. Rheim, Germany: Boehringer Ingelheim Pharmaceuticals, Inc. 2013.
31. Bortezomib (Velcade) FDA Package Insert. Cambridge, MA: Millennium Pharmaceutical. 2014.
32. Zykadia (Ceritinib) FDA Package Insert. Basel, Switzerland: Novartis. 2015.
33. Xalkori (Crizotinib) FDA Package Insert. New York City, NY: Pfizer. 2014.
34. Dabrafenib (Tafinlar) FDA Package Insert. Brentford, UK: GlaxoSmithKline. 2014.
35. Sprycel (Dasatinib) FDA Package Insert. New York City, NY: Bristol-Myers Squibb. 2015.
36. Tarceva (Erlotinib) FDA Package Insert. Famingdale, NY: OSI Pharmaceuticals Inc. 2013.
37. Iressa (Gefitinib) FDA Package Insert. London, UK: AstraZeneca. 2015.
38. Gleevec (Imatinib) FDA Package Insert. Basel, Switzerland: Novartis. 2015.
39. Tasigna (Nilotinib) FDA Package Insert. Basel, Switzerland: Novartis. 2010.
40. Mekinist (Trametinib) FDA Label Insert. London, UK: GlaxoSmithKline. 2014.
41. Caprelsa (Vandetanib) FDA Package Insert. London, UK: AstraZeneca. 2014.
42. Zelboraf (Vemurafenib) FDA Package Insert. San Francisco, CA: Genentech. 2014.
43. Erbitux (Cetuximab) FDA Package Insert. New York City, NY: Bristol-Myers Squibb. 2013.
44. Yervoy (Ipilimumab) FDA Package Insert. New York City, NY: Bristol-Myers Squibb. 2015.
45. Vectibix (Panitumumab) FDA Package Insert. Thousand Oaks, CA: Amgen. 2014.
46. Perjeta (Pertuzumab) FDA Package Insert. San Francisco, CA: Genentech. 2013.
47. Rituxan (Rituximab) FDA Package Insert. San Francisco, CA: Genentech. 2014.
48. Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, Grossi F. Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2014; 15: 889-903.
49. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013; 31: 3335-41.
50. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014; 25: 1813-20.
51. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370: 1189-97.
52. Richly H, Kim TM, Schuler M, Kim DW, Harrison SJ, Shaw AT, Boral AL, Yovine A, Solomon B. Ceritinib in patients with advanced anaplastic lymphoma kinaserearranged anaplastic large-cell lymphoma. Blood. 2015; 126: 1257-8.
53. Cooper MR, Chim H, Chan H, Durand C. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Ann Pharmacother. 2015; 49: 107-12.
54. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13: 1011-9.
55. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385-94.
56. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362: 2260-70.
57. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531-41.
58. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010; 11: 521-9.
59. Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012; 13: 1161-70.
60. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004; 22: 3238-47.
61. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-46.
62. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-32.
63. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008; 372: 1809-18.
64. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-57.
65. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527-37.
66. Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005; 19: 729-38.
67. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213-23.
68. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008; 26: 626-32.
69. Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, von Mehren M, Maki RG, Pisters PW, DeMatteo RP. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. 2010 ASCO Annual Meeting. 2010.
70. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003; 19: 371-5.
71. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-9.
72. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13: 782-9.
73. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367: 107-14.
74. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13: 773-81.
75. Michalarea V, de Miguel Luken MJ, Diamantis N, Garg A, Maubon L, Yap TA, Molife LR, De Bono JS, Ursell P, Banerji U. Ocular toxicity with MEK inhibitors in phase I trials: a single centre experience across six clinical trials. 2015 ASCO Annual Meeting. 2015.
76. Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, Garnett C, Liu Q, Booth B, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012; 18: 3722-30.
77. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandala M, Hospers GA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014; 15: 436-44.
78. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014; 15: 323-32.
79. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007; 110: 980-8.
80. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007; 25: 1350-6.
81. Imbruvica (Ibrutinib) FDA Package Insert. Sunnyvale, CA: Pharmacyclics. 2015.